Genotypic and phenotypic characterization of HIV-1 CRF01-AE env molecular clones from infections in China

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 4, 2010, Pages 440-450

  Nie, Jianhui ^a   Zhang, Chuntao ^a   Liu, Wei ^b   Wu, Xueling ^a   Li, Feng ^b   Wang, Suting ^a   Liang, Fuxiong ^b   Song, Aijing ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Coreceptor tropism; CRF01 AE; HIV 1; Neutralizing antibody; Pseudovirus

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; CHINA; ENVELOPE GENE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; CHINA; CLONING, MOLECULAR; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; RECEPTORS, HIV; VIROSOMES;

EID: 77949348508     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181cb8300     Document Type: Article

References (32)

1. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995;171:1387-1398.
2. Bradney AP, Scheer S, Crawford JM, et al. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogres-sors. J Infect Dis. 1999;179:1264-1267.
3. Zhang YJ, Fracasso C, Fiore JR, et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis. 1997;176:1180-1187.
4. Mascola JR, D'Souza P, Gilbert P, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005;79:10103-10107.
5. Fenyo EM, Heath A, Dispinseri S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE. 2009;4:e4505.
6. Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature. 2008;455:609-611.
7. Lau KA, Wang B, Saksena NK. Emerging trends of HIV epidemiology in Asia. AIDS Rev. 2007;9:218-229.
8. Chong H, Hong K, Zhang C, et al. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr. 2008;47:535-543.
9. Biswas P, Tambussi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother. 2007;8:923-933.
10. Stephenson J. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA. 2007;297:1535-1536.
11. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions\review of the literature. Eur J Med Res. 2007;12:409-417.
12. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
13. Platt EJ, Wehrly K, Kuhmann SE, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:2855-2864.
14. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-312.
15. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
16. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, et al. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01-AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect. 2009;11:334-343.
17. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79: 10108-10125.
18. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80:11776-11790.
19. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, et al. Genotypic characterization of CRF01-AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand. AIDS Res Hum Retroviruses. 2009;25:229-236.
20. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother. 2006;57:619-627.
21. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005;79:6528-6531.
22. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266:1024-1027.
23. Mo H, Stamatatos L, Ip JE, et al. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol. 1997;71:6869-6874.
24. Gray ES, Meyers T, Gray G, et al. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006;3:e255.
25. Sanders RW, Venturi M, Schiffner L, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol. 2002;76:7293-7305.
26. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67:6642-6647.
27. Zwick MB, Jensen R, Church S, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 2005;79:1252-1261.
28. Lorizate M, Gomara MJ, de la Torre BG, et al. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J Mol Biol. 2006;360:45-55.
29. Neurath AR, Strick N, Lin K, et al. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res Hum Retroviruses. 1995;11:687-696.
30. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001;75: 10892-10905.
31. Brunel FM, Zwick MB, Cardoso RM, et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol. 2006;80:1680-1687.
32. Blish CA, Nedellec R, Mandaliya K, et al. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS. 2007;21:693-702.